Mylan N.V. was a big mover last session, as the company saw its shares rise more than 16% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This breaks the recent trend of the company, as the stock is now trading above the volatile price range of $30.86 to $33.60 in the past one-month time frame.

The upside came after the company won the U.S. regulators’ approval for its generic version of Teva Pharmaceutical’s multiple sclerosis drug Copaxone.

The company has not seen any estimate revisions over the past month, while the Zacks Consensus Estimate for the current quarter also remained unchanged. The recent price action is encouraging though, so make sure to keep a close watch on this firm in the near future.

Mylan currently has a Zacks Rank #5 (Strong Sell), while its Earnings ESP is negative.

A better-ranked stock in the Medical - Generic Drugs industry is AxoGen, Inc. (AXGN Quick QuoteAXGN - Free Report) , which currently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Is MYL going up? Or down? Predict to see what others think: Up or Down

4 Stocks to Watch after the Massive Equifax Hack
 
Cybersecurity stocks spiked on recent news of a data breach affecting 143 million Americans. But which stocks are the best buy candidates right now? And what does the future hold for the cybersecurity industry?
 
Equifax is just the most recent victim. Computer hacking and identity theft are more common than ever. Zacks has just released Cybersecurity! An Investor’s Guide to inform Zacks.com readers about this $170 billion/year space. More importantly, it highlights 4 cybersecurity picks with strong profit potential.
 
Get the new Investing Guide now>>